Pfizer director Shantanu Narayen received an award of 1,743.983 phantom stock units on September 25, 2026, according to an SEC insider filing published September 29, 2026. The reported price was $28.67 per unit, putting the transaction's value at approximately $50,000.

The disclosure concerns Pfizer Inc., whose ticker is PFE. The supplied SEC summary classifies the transaction as an award or grant. That classification is central to reading the disclosure: it describes units received through an award, rather than an open-market purchase of Pfizer shares.

What the disclosure reports

Narayen is identified as a Pfizer director in the SEC source. The reported transaction involves phantom stock units, and the supplied summary indicates that no Rule 10b5-1 plan was associated with it.

The September 25 transaction date and September 29 filing publication date refer to different events. The first identifies when the award occurred; the second identifies when the supplied filing item was published. Keeping those dates separate avoids presenting the publication date as the award date.

Multiplying the disclosed unit count by the reported price produces approximately $50,000, consistent with the value in the source summary. That amount describes the reported award value; the summary does not identify a cash payment to Narayen.

What the summary cannot establish

The supplied material does not specify vesting conditions, settlement terms or whether the units ultimately settle in cash or shares. It also does not provide Narayen's total Pfizer holdings after the transaction. Those details cannot be inferred from the unit count and price alone.

Analysis: The award classification limits what readers can conclude about investment intent. This disclosure alone does not establish that Narayen committed personal funds to buying Pfizer stock or expressed a view on its future performance.

What to watch

For a fuller assessment, the relevant details would be the award's vesting and settlement provisions and any accompanying ownership information. Those terms are not included in the supplied summary, so conclusions about eventual proceeds or changes in share ownership remain unsupported.